Mahmoudi Ali, Moallem Seyed Adel, Johnston Thomas P, Sahebkar Amirhossein
Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Iran.
PPAR Res. 2022 Jun 17;2022:5805398. doi: 10.1155/2022/5805398. eCollection 2022.
Nonalcoholic fatty liver disease (NAFLD) is initiated by excessive fat buildup in the liver, affecting around 35% of the world population. Various circumstances contribute to the initiation and progression of NAFLD, and it encompasses a wide range of disorders, from simple steatosis to nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer. Although several treatments have been proposed, there is no definitive cure for NAFLD. In recent decades, several medications related to other metabolic disorders have been evaluated in preclinical studies and in clinical trials due to the correlation of NAFLD with other metabolic diseases. Fenofibrate is a fibrate drug approved for dyslipidemia that could be used for modulation of hepatic fat accumulation, targeting peroxisome proliferator-activator receptors, and de novo lipogenesis. This drug offers potential therapeutic efficacy for NAFLD due to its capacity to decrease the accumulation of hepatic lipids, as well as its antioxidant, anti-inflammatory, and antifibrotic properties. To better elucidate the pathophysiological processes underlying NAFLD, as well as to test therapeutic agents/interventions, experimental animal models have been extensively used. In this article, we first reviewed experimental animal models that have been used to evaluate the protective effects of fenofibrate on NAFLD/NASH. Next, we investigated the impact of fenofibrate on the hepatic microcirculation in NAFLD and then summarized the beneficial effects of fenofibrate, as compared to other drugs, for the treatment of NAFLD. Lastly, we discuss possible adverse side effects of fenofibrate on the liver.
非酒精性脂肪性肝病（NAFLD）是由肝脏中脂肪过度堆积引发的，影响着全球约35%的人口。多种情况会导致NAFLD的发生和发展，它涵盖了从单纯性脂肪肝到非酒精性脂肪性肝炎（NASH）、肝硬化和肝癌等广泛的病症。尽管已经提出了几种治疗方法，但NAFLD尚无确切的治愈方法。近几十年来，由于NAFLD与其他代谢性疾病的相关性，几种与其他代谢紊乱相关的药物已在临床前研究和临床试验中进行了评估。非诺贝特是一种被批准用于治疗血脂异常的贝特类药物，可用于调节肝脏脂肪堆积，作用于过氧化物酶体增殖物激活受体，并抑制从头脂肪生成。这种药物因其能够减少肝脏脂质的积累以及具有抗氧化、抗炎和抗纤维化特性，而为NAFLD提供了潜在的治疗效果。为了更好地阐明NAFLD潜在的病理生理过程，以及测试治疗药物/干预措施，实验动物模型已被广泛使用。在本文中，我们首先回顾了用于评估非诺贝特对NAFLD/NASH保护作用的实验动物模型。接下来，我们研究了非诺贝特对NAFLD肝脏微循环的影响，然后总结了与其他药物相比，非诺贝特在治疗NAFLD方面的有益效果。最后，我们讨论了非诺贝特对肝脏可能产生的不良副作用。
